Rinvoq (upadacitinib) is processed primarily by a liver enzyme called CYP3A4, which means any drug, food, or supplement that speeds up or slows down that enzyme can change how much Rinvoq ends up in your bloodstream. Strong CYP3A4 inhibitors push levels higher, strong inducers pull them lower, and both scenarios create real clinical problems. The interaction profile is actually narrower than many people expect, but the interactions that do exist matter enough that your prescriber needs a full picture of everything you take.
Why One Liver Enzyme Controls Most Rinvoq Interactions
Your liver uses a family of enzymes to break down medications, and CYP3A4 is one of the busiest. Upadacitinib relies heavily on CYP3A4 for its breakdown, with a smaller contribution from another enzyme called CYP2D6.1PubMed Central. Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication Because CYP3A4 does the heavy lifting, anything that interferes with that enzyme’s activity has a direct effect on how quickly your body clears Rinvoq. Hundreds of commonly prescribed drugs either inhibit or induce CYP3A4, which is why your pharmacist or doctor will scrutinize your medication list before you start treatment.
The practical consequence is straightforward. If something blocks CYP3A4, Rinvoq hangs around longer and reaches higher concentrations than intended. If something revs CYP3A4 up, Rinvoq gets broken down too quickly and may not work as well. Both of these scenarios can be managed, but they require awareness and, in some cases, dose changes.
Drugs That Raise Rinvoq Levels
Strong CYP3A4 inhibitors are the most clinically significant interaction partners for Rinvoq. These drugs slow the enzyme down enough that upadacitinib accumulates to roughly double its normal concentration. The list includes certain antifungal medications like ketoconazole and itraconazole, the antibiotic clarithromycin, and HIV protease inhibitors such as ritonavir. When you take one of these alongside Rinvoq, the prescribing guidance calls for cutting the Rinvoq dose. For most approved indications, the standard 15 mg once-daily dose drops to 15 mg if you were on the higher 30 mg dose, or remains at 15 mg with closer monitoring if that was already your dose.
Moderate CYP3A4 inhibitors raise Rinvoq levels too, but to a lesser degree. Drugs like fluconazole, erythromycin, verapamil, and diltiazem fall into this category. The increase is smaller than with strong inhibitors, and routine dose adjustments are not always required, but your prescriber should still know about them. The concern is not just about peak blood levels but about sustained exposure over time, since Rinvoq is taken daily and even a modest bump in drug concentration compounds day after day.
Research on other JAK inhibitors in the same drug class provides a useful warning. A large study of over 7,500 patients found that when tofacitinib or baricitinib were used alongside strong CYP3A4 or CYP2C19 inhibitors, the risk of stopping treatment due to problems rose by 41% to 144%, and the risk of pneumonia climbed as well.2Joint Bone Spine. Impact of drug-drug interaction of JAK inhibitors, CYP enzyme inhibitors and OAT3 inhibitors on persistence and infection rates in patients with autoimmune rheumatic diseases The pneumonia finding with CYP2C19 inhibitors extended across all JAK inhibitors studied. While upadacitinib has a somewhat different metabolic profile than tofacitinib, these results reinforce why CYP-mediated interactions with JAK inhibitors deserve careful attention rather than casual dismissal.
Drugs That Lower Rinvoq Levels
On the opposite side, strong CYP3A4 inducers speed up the enzyme so much that Rinvoq gets cleared from your system before it can do its job. Rifampin, used for tuberculosis, is the classic example and roughly halves upadacitinib exposure. The anti-seizure medications phenytoin and carbamazepine are strong inducers too, as is the herbal supplement St. John’s wort. Unlike the inhibitor situation, where a dose reduction can compensate, there is no approved higher dose of Rinvoq to offset the effect of a strong inducer. The guidance is simply to avoid the combination when possible.
This is a genuinely tricky spot for people who need both drugs. If you are taking rifampin for an active tuberculosis infection, switching to a different JAK inhibitor with a different metabolic pathway could be an option your doctor considers. If you’re on an anti-seizure drug, the conversation gets more nuanced because switching seizure medications is not trivial. These are the kinds of interactions where the clinical answer is not a formula but a risk-benefit discussion between you and your care team.
Moderate inducers like efavirenz or bosentan reduce Rinvoq levels to a lesser extent. The clinical impact is less clear-cut, and formal dose adjustment recommendations for moderate inducers are not as firmly established. That ambiguity is worth flagging to your prescriber rather than ignoring.
Immunosuppressants and Biologics
Rinvoq already suppresses part of your immune system by blocking JAK1 signaling, so layering additional immunosuppressive drugs on top raises the risk of serious infections. The prescribing information specifically warns against combining upadacitinib with other potent immunosuppressants such as azathioprine, cyclosporine, or biologic therapies like TNF blockers, IL-17 inhibitors, or IL-23 inhibitors. This is not a pharmacokinetic interaction in the traditional sense. Neither drug changes the blood level of the other. The concern is pharmacodynamic: both drugs push the immune system in the same direction, and the combined effect can leave you more vulnerable to infections than either drug alone would.
Methotrexate is the notable exception. Rinvoq is commonly prescribed alongside methotrexate for rheumatoid arthritis, and this combination has been studied extensively in clinical trials. The two drugs do not meaningfully alter each other’s blood levels, and the combination is part of the approved treatment approach. Conventional synthetic disease-modifying drugs like methotrexate and sulfasalazine are generally considered acceptable partners for Rinvoq, while biologic DMARDs are not.
Live vaccines are another area of concern. Because Rinvoq dampens immune responses, a live vaccine could potentially cause the very infection it is meant to prevent. If you need a live vaccine, your doctor will want to time it before you start Rinvoq or during a treatment break. Inactivated vaccines, by contrast, are safe to give during treatment, though the immune response may be somewhat blunted.
Hormonal Birth Control
Some immunosuppressive and anti-inflammatory drugs interfere with oral contraceptives, which makes this a natural question for anyone taking Rinvoq who relies on hormonal birth control. The evidence here is reassuring. A dedicated pharmacokinetic study in healthy women found that upadacitinib at 30 mg daily had no meaningful effect on the blood levels of ethinylestradiol or levonorgestrel, the two most common components of combination birth control pills. The measured drug levels with and without Rinvoq fell well within the standard boundaries used to confirm that two drugs do not interact.3PubMed Central. The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects
This means you do not need to switch contraceptive methods or add backup protection because of Rinvoq itself. However, if you are also taking a CYP3A4 inducer alongside Rinvoq for any reason, that inducer might independently affect your contraceptive’s effectiveness, since ethinylestradiol is itself metabolized by CYP3A4. In that scenario, the interaction concern is with the inducer, not with Rinvoq.
Food, Grapefruit, and Herbal Supplements
You can take Rinvoq with or without food. A pharmacokinetic study showed that a high-fat meal lowered the peak blood level of upadacitinib by about 23%, but the total amount of drug absorbed over time was unchanged.4PubMed Central. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib In practical terms, a fatty breakfast might slow how quickly the drug kicks in on a given day, but it does not reduce how much drug your body ultimately uses. The extended-release formulation used in practice smooths out these meal-related fluctuations even further, so meal timing is not something you need to stress about.
Grapefruit and grapefruit juice are worth mentioning because they inhibit CYP3A4 in the gut wall. The effect of grapefruit is generally moderate and variable from person to person and from batch to batch of juice. It is unlikely to cause the same degree of interaction as a strong prescription inhibitor like ketoconazole, but drinking large amounts regularly could nudge Rinvoq levels higher. If you enjoy occasional grapefruit, a small glass now and then is unlikely to cause trouble, but daily consumption in large quantities is worth discussing with your doctor.
St. John’s wort, a popular herbal remedy for mild depression, is a potent CYP3A4 inducer and falls squarely into the “avoid” category. It can substantially reduce Rinvoq’s effectiveness. This is the same mechanism as rifampin, just from a product you can buy without a prescription. The fact that it is sold as a supplement rather than a drug does not make the interaction any less real. If you are considering St. John’s wort for mood support, talk to your prescriber about alternatives that do not interfere with CYP3A4.
Kidney Function and Drug Clearance
Because Rinvoq is processed mainly by the liver, you might expect kidney problems to have little impact on its levels. That is mostly true, but not entirely. A study that specifically examined upadacitinib in people with varying degrees of kidney impairment found that severe impairment raised total drug exposure by about 44% compared to people with normal kidney function, while peak levels were not significantly affected.5PubMed Central. Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics Despite this increase, the researchers concluded that dose adjustment was not warranted for kidney impairment based on the drug’s safety and efficacy data.
That said, if you have severe kidney disease and are also taking a moderate CYP3A4 inhibitor, the combined effect could push levels higher than either factor alone. Kidney impairment is not a standalone interaction, but it changes the baseline. Your doctor may want to monitor more carefully or lean toward conservative dosing if multiple factors are stacking up.
Rinvoq is not recommended for people with end-stage kidney disease on dialysis, not because of a known dangerous interaction but because there is limited data in that population. The drug has not been adequately studied in people undergoing dialysis, so prescribers generally avoid it in that setting.
Liver Impairment Is a Different Story
Since CYP3A4 lives primarily in the liver, liver disease has a more direct impact on Rinvoq metabolism than kidney disease does. Mild to moderate liver impairment does not require dose adjustment, but severe hepatic impairment is a contraindication. If your liver cannot process CYP3A4 substrates efficiently, Rinvoq accumulates unpredictably, and the extended-release formulation’s absorption profile may also behave differently. This is not a drug interaction in the traditional medication-versus-medication sense, but it is a critical consideration for anyone with liver conditions like cirrhosis or severe hepatitis.
Alcohol, while not a direct CYP3A4 interaction concern at moderate intake, can contribute to liver inflammation over time. If you are on Rinvoq and drink regularly, the combined load on your liver is worth mentioning to your doctor, especially during routine blood monitoring.
Medications That Do Not Interact
It is just as useful to know what does not interact with Rinvoq as to know what does. Proton pump inhibitors like omeprazole, which raise gastric pH, do not meaningfully affect upadacitinib absorption. Rinvoq’s extended-release tablet is designed to release the drug in a way that is not sensitive to stomach acidity, so you can take your acid reflux medication without concern.
Statins, commonly used for cholesterol, are metabolized by various CYP enzymes depending on the specific statin. Atorvastatin and simvastatin are CYP3A4 substrates, which raises the question of whether Rinvoq might affect their levels. Upadacitinib is not a significant inhibitor or inducer of CYP3A4 at therapeutic doses. It is a substrate of the enzyme, not a modifier of it. This means Rinvoq does not change how quickly your body processes atorvastatin or other CYP3A4-dependent statins. You can take both together without dose adjustments to either medication.
NSAIDs like ibuprofen or naproxen, which many people with inflammatory conditions take for symptom relief, do not have a pharmacokinetic interaction with Rinvoq. The caution with NSAIDs is pharmacodynamic: JAK inhibitors may increase the risk of gastrointestinal perforations, and NSAIDs carry their own gastrointestinal risk. The combination is not forbidden, but your doctor will weigh whether you still need the NSAID once Rinvoq is controlling your inflammation.
Practical Steps for Managing Interactions
The most important thing you can do is keep a complete, current list of every medication, supplement, and herbal product you take and share it with every prescriber and pharmacist involved in your care. Rinvoq’s interaction profile is not unusually complicated, but the consequences of a missed CYP3A4 interaction can include both treatment failure and increased side effects, including a higher susceptibility to infections.
If you are prescribed a new medication while on Rinvoq, a quick check against the CYP3A4 inhibitor and inducer lists can flag potential problems before they start. Many pharmacy computer systems do this automatically, but the alerts are sometimes overridden or missed. You do not need to memorize enzyme pathways, but knowing that the key phrase to watch for is “strong CYP3A4 inhibitor” or “strong CYP3A4 inducer” gives you a useful filter when reading medication guides or talking to your pharmacist.
Routine blood work while on Rinvoq, including liver function tests, complete blood counts, and lipid panels, serves partly as an indirect monitor for unexpected interactions. If your white blood cell counts drop more than expected or liver enzymes start trending up, a medication interaction is one of the things your doctor will investigate. These labs are already standard practice for anyone on a JAK inhibitor, so they serve double duty as both safety monitoring and interaction surveillance.
How Rinvoq Compares to Other JAK Inhibitors on Interactions
Upadacitinib’s reliance on CYP3A4 is shared by tofacitinib (Xeljanz), which is also substantially metabolized by CYP3A4 and CYP2C19. Baricitinib (Olumiant), by contrast, is mostly cleared by the kidneys and has fewer CYP-related interactions, though it interacts with drugs that affect a kidney transporter called OAT3. The large study of JAK inhibitor drug interactions in patients with autoimmune conditions found that CYP enzyme inhibitors had a clinically visible impact on both treatment persistence and infection rates across the class, but the specific drugs and enzymes involved varied.6Joint Bone Spine. Impact of drug-drug interaction of JAK inhibitors, CYP enzyme inhibitors and OAT3 inhibitors on persistence and infection rates in patients with autoimmune rheumatic diseases
This matters if you are switching between JAK inhibitors or if your doctor is choosing one for the first time. A person already taking a strong CYP3A4 inhibitor they cannot stop might do better on baricitinib, which sidesteps that enzyme. Someone with significant kidney disease might be a better candidate for upadacitinib, whose clearance depends more on the liver. The interaction profile is one piece of the puzzle, not the whole picture, but it is a piece that sometimes tips the decision.